A live attenuated strain of Yersinia pestis KIM as a vaccine against plague

被引:36
|
作者
Sun, Wei [1 ]
Six, David [2 ]
Kuang, Xiaoying [1 ]
Roland, Kenneth L. [1 ]
Raetz, Christian R. H. [2 ]
Curtiss, Roy, III [1 ]
机构
[1] Arizona State Univ, Ctr Infect Dis & Vaccinol, Biodesign Inst, Tempe, AZ 85287 USA
[2] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
Yersinia pestis; Lipid A; Regulated delayed attenuation; Plague vaccine; RECOMBINANT V-ANTIGEN; ESCHERICHIA-COLI; PNEUMONIC PLAGUE; PROTECTS MICE; MOUSE MODEL; VIRULENCE; IMMUNIZATION; IMMUNITY; GENES; IDENTIFICATION;
D O I
10.1016/j.vaccine.2011.01.099
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Yersinia pestis, the causative agent of plague, is a potential weapon of bioterrorism. Y. pestis evades the innate immune system by synthesizing tetra-acylated lipid A with poor Toll-like receptor 4 (TLR4)-stimulating activity at 37 degrees C, whereas hexa-acylated lipid A, a potent TLR4 agonist, is made at lower temperatures. Synthesis of Escherichia coli LpxL, which transfers the secondary laurate chain to the 2'-position of lipid A, in Y. pestis results in production of hexa-acylated lipid A at 37 degrees C, leading to significant attenuation of virulence. Previously, we described a Y. pestis vaccine strain in which crp expression is under the control of the arabinose-regulated araC P-BAD promoter, resulting in a 4-5 log reduction in virulence. To reduce the virulence of the crp promoter mutant further, we introduced E. coli lpxL into the Y. pestis chromosome. The chi 10030( pCD1Ap) (Delta lpxP32::P-lpxL lpxL Delta P-crp21::TT araC P-BAD crp) construct likewise produced hexa-acylated lipid A at 37 degrees C and was significantly more attenuated than strains harboring each individual mutation. The LD50 of the mutant in mice, when administered subcutaneously or intranasally was > 10(7)-times and > 10(4)-times greater than wild type, respectively. Mice immunized subcutaneously with a single dose of the mutant were completely protected against a subcutaneous challenge of 3.6 x 10(7) wild-type Y. pestis and significantly protected (80% survival) against a pulmonary challenge of 1.2 x 10(4) live cells. Intranasal immunization also provided significant protection against challenges by both routes. This mutant is an immunogenic, highly attenuated live Y. pestis construct that merits further development as a vaccine candidate. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2986 / 2998
页数:13
相关论文
共 50 条
  • [21] A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs
    Feodorova, V. A.
    Pan'kina, L. N.
    Savostina, E. P.
    Sayapina, L. V.
    Motin, V. L.
    Dentovskaya, S. V.
    Shaikhutdinova, R. Z.
    Ivanov, S. A.
    Lindner, B.
    Kondakova, A. N.
    Bystrova, O. V.
    Kocharova, N. A.
    Senchenkova, S. N.
    Holst, O.
    Pier, G. B.
    Knirel, Y. A.
    Anisimov, A. P.
    VACCINE, 2007, 25 (44) : 7620 - 7628
  • [22] Developing live vaccines against Yersinia pestis
    Sun, Wei
    Roland, Kenneth L.
    Curtiss, Roy, III
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2011, 5 (09): : 614 - 627
  • [23] Correlates of Immunity Elicited by Live Yersinia pestis Vaccine
    Braciale, Vivian L.
    Nash, Michael
    Sinha, Namita
    Zudina, Irina V.
    Motin, Vladimir L.
    NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH, VOL 1: FRONTIERS IN RESEARCH, 2008, : 473 - +
  • [24] Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica
    Branger, Christine G.
    Torres-Escobar, Ascencion
    Sun, Wei
    Perry, Robert
    Fetherston, Jacqueline
    Roland, Kenneth L.
    Curtiss, Roy, III
    VACCINE, 2009, 27 (39) : 5363 - 5370
  • [25] Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine
    Feodorova, Valentina A.
    Lyapina, Anna M.
    Khizhnyakova, Maria A.
    Zaitsev, Sergey S.
    Sayapina, Lidiya V.
    Arseneva, Tatiana E.
    Trukhachev, Alexey L.
    Lebedeva, Svetlana A.
    Telepnev, Maxim V.
    Ulianova, Onega V.
    Lyapina, Elena P.
    Ulyanov, Sergey S.
    Motin, Vladimir L.
    PLOS NEGLECTED TROPICAL DISEASES, 2018, 12 (06):
  • [26] A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection
    Oyston, Petra C. F.
    Mellado-Sanchez, Gabriela
    Pasetti, Marcela F.
    Nataro, James P.
    Titball, Richard W.
    Atkins, Helen S.
    MICROBIAL PATHOGENESIS, 2010, 48 (05) : 191 - 195
  • [27] Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague
    Garmory, HS
    Griffin, KF
    Brown, KA
    Titball, RW
    VACCINE, 2003, 21 (21-22) : 3051 - 3057
  • [28] Yersinia pestis with Regulated Delayed Attenuation as a Vaccine Candidate To Induce Protective Immunity against Plague
    Sun, Wei
    Roland, Kenneth L.
    Kuang, Xiaoying
    Branger, Christine G.
    Curtiss, Roy, III
    INFECTION AND IMMUNITY, 2010, 78 (03) : 1304 - 1313
  • [29] Lethally-irradiated Yersinia pestis immunization protects against the plague: a novel vaccine candidate
    Lambert, Nathaniel Dane
    Nilles, Matthew L.
    Bradley, David Sherman
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [30] Yersinia pestis (plague) vaccines
    Titball, RW
    Williamson, ED
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (06) : 965 - 973